1. Home
  2. GBIO vs CCM Comparison

GBIO vs CCM Comparison

Compare GBIO & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • CCM
  • Stock Information
  • Founded
  • GBIO 2016
  • CCM 1997
  • Country
  • GBIO United States
  • CCM China
  • Employees
  • GBIO N/A
  • CCM N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • CCM Medical/Nursing Services
  • Sector
  • GBIO Health Care
  • CCM Health Care
  • Exchange
  • GBIO Nasdaq
  • CCM Nasdaq
  • Market Cap
  • GBIO 29.2M
  • CCM 33.3M
  • IPO Year
  • GBIO 2020
  • CCM 2009
  • Fundamental
  • Price
  • GBIO $0.38
  • CCM $5.50
  • Analyst Decision
  • GBIO Strong Buy
  • CCM
  • Analyst Count
  • GBIO 4
  • CCM 0
  • Target Price
  • GBIO $7.33
  • CCM N/A
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • CCM 2.3K
  • Earning Date
  • GBIO 08-06-2025
  • CCM 04-25-2025
  • Dividend Yield
  • GBIO N/A
  • CCM N/A
  • EPS Growth
  • GBIO N/A
  • CCM N/A
  • EPS
  • GBIO N/A
  • CCM N/A
  • Revenue
  • GBIO $24,556,000.00
  • CCM $52,603,198.00
  • Revenue This Year
  • GBIO N/A
  • CCM N/A
  • Revenue Next Year
  • GBIO N/A
  • CCM N/A
  • P/E Ratio
  • GBIO N/A
  • CCM N/A
  • Revenue Growth
  • GBIO 146.47
  • CCM N/A
  • 52 Week Low
  • GBIO $0.30
  • CCM $3.80
  • 52 Week High
  • GBIO $3.65
  • CCM $10.50
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 52.02
  • CCM 37.76
  • Support Level
  • GBIO $0.32
  • CCM $5.50
  • Resistance Level
  • GBIO $0.36
  • CCM $5.68
  • Average True Range (ATR)
  • GBIO 0.03
  • CCM 0.18
  • MACD
  • GBIO 0.00
  • CCM 0.02
  • Stochastic Oscillator
  • GBIO 81.00
  • CCM 37.83

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

Share on Social Networks: